201 related articles for article (PubMed ID: 10506721)
1. A phase II trial of methotrexate, cisplatin, 5-fluorouracil, and leucovorin in the treatment of invasive and metastatic urothelial carcinoma.
Oh WK; Manola J; Richie JP; Loughlin KR; Kantoff PW
Cancer; 1999 Oct; 86(7):1329-34. PubMed ID: 10506721
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS
J Urol; 2007 Jan; 177(1):84-9; discussion 89. PubMed ID: 17162009
[TBL] [Abstract][Full Text] [Related]
3. A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Small EJ; Fippin LJ; Ernest ML; Carroll PR
Cancer; 1996 Oct; 78(8):1775-80. PubMed ID: 8859191
[TBL] [Abstract][Full Text] [Related]
4. Weekly cisplatin plus infusional high-dose 5-fluorouracil and leucovorin (P-HDFL) for metastatic urothelial carcinoma: an effective regimen with low toxicity.
Lin CC; Hsu CH; Huang CY; Cheng AL; Chen J; Vogelzang NJ; Pu YS
Cancer; 2006 Mar; 106(6):1269-75. PubMed ID: 16470604
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
[TBL] [Abstract][Full Text] [Related]
6. Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
Kyriakakis Z; Dimopoulos MA; Kostakopoulos A; Karayiannis A; Sofras F; Zervas A; Giannopoulos A; Dimopoulos C
J Urol; 1997 Aug; 158(2):408-11. PubMed ID: 9224313
[TBL] [Abstract][Full Text] [Related]
7. Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer.
Chen WC; Liaw CC; Chuang CK; Chen MF; Chen CS; Lin PY; Chang PL; Chu SH; Wu CT; Hong JH
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):726-33. PubMed ID: 12788178
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
9. [Clinical study of combination chemotherapy of methotrexate, epirubicin and nedaplatin (MEN) in patients with advanced urothelial carcinoma].
Hattori Y; Takizawa A; Kishida T; Kakizoe M; Fujikawa N; Teranishi J; Kondo K; Saito K; Noguchi K; Nakaigawa N; Kubota Y
Gan To Kagaku Ryoho; 2007 May; 34(5):739-43. PubMed ID: 17496448
[TBL] [Abstract][Full Text] [Related]
10. [Sequential methotrexate and 5-fluorouracil, doxorubicin, and cisplatin for advanced urothelial cancer].
Nishiyama T; Sasagawa T; Tanikawa T; Katayama Y; Kawakami Y; Tomita Y; Terunuma M; Kimura M; Sato S; Osawa T
Nihon Hinyokika Gakkai Zasshi; 1992 Mar; 83(3):352-7. PubMed ID: 1564837
[TBL] [Abstract][Full Text] [Related]
11. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen.
Adamo V; Magno C; Spitaleri G; Garipoli C; Maisano C; Alafaci E; Adamo B; Rossello R; Scandurra G; Scimone A
Oncology; 2005; 69(5):391-8. PubMed ID: 16319510
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) as second-line therapy for patients with advanced urothelial cancer.
Zhang S; Xue H; Chen Q
Oncotarget; 2016 Sep; 7(36):58579-58585. PubMed ID: 27409828
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate and leucovorin double-modulated 5-fluorouracil combined with cisplatin (MPFL) in metastatic/recurrent head and neck cancer.
Chang PM; Teng HW; Chen PM; Chang SY; Chu PY; Tsai TL; Tai SK; Wang YF; Huang JL; Yang MH
J Chin Med Assoc; 2008 Jul; 71(7):336-41. PubMed ID: 18653395
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of cisplatin, methotrexate, levofolinic acid, and 5-fluorouracil in the treatment of patients with locally advanced, metastatic squamous cell carcinoma of the head and neck.
Caponigro F; Comella P; Marcolin P; Russo Spena F; Biglietto M; Cartenì G; De Lucia L; Avallone A; Gravina A; Comella G
Cancer; 1999 Feb; 85(4):952-9. PubMed ID: 10091775
[TBL] [Abstract][Full Text] [Related]
18. Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial.
Loehrer PJ; Elson P; Dreicer R; Hahn R; Nichols CR; Williams R; Einhorn LH
J Clin Oncol; 1994 Mar; 12(3):483-8. PubMed ID: 7509853
[TBL] [Abstract][Full Text] [Related]
19. Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer.
Bellmunt J; Cos J; Clèries R; Pérez M; Ribas A; Eres N; Murio JE; Margarit C; Baselga J
Cancer Invest; 2002; 20(5-6):673-85. PubMed ID: 12197223
[TBL] [Abstract][Full Text] [Related]
20. Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP).
Tu SM; Millikan RE; Pagliaro LC; Daliani D; Papandreou CN; Kim J; Chen DT; Williams DL; Logothetis CJ
Urol Oncol; 2003; 21(5):342-8. PubMed ID: 14670540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
